Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas

1476-4598-7-13 1476-4598 Research Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas Console M Gloria gconsole2@gmail.com Herenu B Claudia c_herenu@yahoo.com Camihort A Gisela hdelzotto@yahoo.com.ar Luna C Georgina geolu@yahoo.com.ar Bracamonte I Maria zulema@netverk.com.ar Morel R Gustavo gustavmorel@hotmail.com Goya G Rodolfo rgoya@netverk.com.ar

Department of Cytology, Histology & Embryology B-CICBA, National University of La Plata, CC455; (1900) La Plata, Argentina

INIBIOLP, Faculty of Medicine, National University of La Plata, CC455; (1900) La Plata, Argentina

Molecular Cancer 1476-4598 2008 7 1 13 http://www.molecular-cancer.com/content/7/1/13 18218140 10.1186/1476-4598-7-13 15 9 2007 25 1 2008 25 1 2008 2008 Console et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The implementation of gene therapy for the treatment of pituitary tumors emerges as a promising complement to surgery and may have distinct advantages over radiotherapy for this type of tumors. Up to now, suicide gene therapy has been the main experimental approach explored to treat experimental pituitary tumors. In the present study we assessed the effectiveness of insulin-like growth factor I (IGF-I) gene therapy for the treatment of estrogen-induced prolactinomas in rats.

Results

Female Sprague Dawley rats were subcutaneously implanted with silastic capsules filled with 17-β estradiol (E₂) in order to induce pituitary prolactinomas. Blood samples were taken at regular intervals in order to measure serum prolactin (PRL). As expected, serum PRL increased progressively and 23 days after implanting the E₂capsules (Experimental day 0), circulating PRL had undergone a 3–4 fold increase. On Experimental day 0 part of the E₂-implanted animals received a bilateral intrapituitary injection of either an adenoviral vector expressing the gene for rat IGF-I (RAd-IGFI), or a vector (RAd-GFP) expressing the gene for green fluorescent protein (GFP). Seven days post vector injection all animals were sacrificed and their pituitaries morphometrically analyzed to evaluate changes in the lactotroph population. RAd-IGFI but not RAd-GFP, induced a significant fall in serum PRL. Furthermore, RAd-IGFI but not RAd-GFP significantly reversed the increase in lactotroph size (CS) and volume density (VD) induced by E₂treatment.

Conclusion

We conclude that IGF-I gene therapy constitutes a potentially useful intervention for the treatment of prolactinomas and that bioactive peptide gene delivery may open novel therapeutic avenues for the treatment of pituitary tumors.

Background

Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans, comprising up to 15% of primary intracranial tumors 1 and also are the most prevalent pathology in old female rats 2. In both species, prolactinomas are the most frequent type of pituitary adenoma.

Estrogen exposure has been linked to the formation of prolactinomas in both humans and animals 345. Estrogens, particularly estradiol and diethylstilbestrol, have been shown to induce lactotropic cell tumors within 2–4 weeks in female rats. Women taking oral contraceptives often display increased prolactin (PRL) levels and have increased incidence of prolactinomas, although not all women appear to be equally susceptible to the mitogenic effect of estradiol 67.

There are a number of growth factors that are estrogen-dependent and function in lactotropic proliferation, differentiation, and/or transformation. The relatedness of these factors and the significance of each alone are not well-understood. Some of these estrogen-regulated factors are epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factor alpha (TGF-α), basic fibroblast growth factor (bFGF), interleukin-2 (IL-2), IL-6, fibroblast growth factor-4 (FGF-4), transforming growth factor-β (TGF-β), insulin-like growth factor-I (IGF-I) and IGFI-II 89. Although estrogen is known to up-regulate IGF-I mRNA in normal rat pituitaries 10, large estrogen-induced pituitary adenomas have been reported to possess decreased levels of IGF-I mRNA. Furthermore, partial remission induced by the anti-estrogen tamoxifen was associated with an increase in the pituitary content of IGF-I mRNA of these adenomas 11. Also, it has been shown that in primary cultures of rat lactotrophs, estrogen has an antiproliferative action in the presence of insulin or IGF-I 1213. In view of this evidence, it was of interest to determine whether in vivo overexpression of the gene for rat IGF-I in estrogen-induced rat prolactinomas could be able to restore lacotropic cell morphology and reverse hyperprolactinemia. The present report describes our findings.

Results

Effect of IGF-I gene therapy on pituitary lactotroph morphology

Stereotaxic injection of RAd-GFP (an adenoviral vector expressing a chimeric variant of green fluorescent protein; see Methods) into pituitary adenomas induced a significant expression of GFP around the track of the needle (Fig. 1) without significantly damaging the gland (Fig. 1, inset). As expected, three weeks of estrogen treatment induced a significant increase in pituitary size (data not shown) as well as clear changes in the lactotropic cell population, already evident when pituitary sections were qualitatively assessed (Fig 2). Estrogen-induced pituitary adenomas showed a significant (p < 0.01) increase in lactotropic cell size as compared with their intact counterparts (Fig. 3; also see Fig. 2). Seven days of IGF-I gene therapy significantly reversed this change (p < 0.01) although lactotroph cell surface (CS) was still higher than in intact animals (Fig. 3; also see Fig. 2). Lactotroph volume density (VD) was higher in estrogen-induced pituitary adenomas when compared with the pituitaries of intact animals (Fig. 4). Again, IGF-I gene therapy significantly (p < 0.05) reversed this alteration although lactotroph VD in RAd-IGF-I injected adenomas remained higher than in normal intact glands (Fig. 4).

Figure 1

Expression of transgenic GFP/TK in a pituitary adenoma

Expression of transgenic GFP/TK in a pituitary adenoma. The main panel shows the green fluorescence of transduced cells around the entry point (arrow) of the needle used to stereotaxically deliver RAd-GFP/TK into the tumor Obj. ×20. The inset shows a low magnification view of the same pituitary adenoma where an entry point of the needle can be seen (arrow). No structural damage is evident as a consequence of the injection. Obj. ×4.

Figure 2

Effect of IGF-I gene therapy on lactotropic cells of pituitary adenomas

Effect of IGF-I gene therapy on lactotropic cells of pituitary adenomas. Representative fields of specifically immunostained PRL-cells in the pituitary gland of an intact (Intact) rat, an animal treated with estrogen for 4 weeks (E only), and animal receiving estrogen for 4 weeks and RAd-GFP during the last experimental week (E + RAdGFP) and an animal receiving estrogen for 4 weeks and RAd-IGF-I during the last experimental week (E + RAd-IGF-I). Insets. Higher magnification views of the specimens. EnVision system peroxidase. Bar: 25 μm. Inset: 12.5 μm.

Figure 3

Effect of IGF-I gene therapy on lactotropic cell size

Effect of IGF-I gene therapy on lactotropic cell size. Lactotroph cell surface (CS) in the pituitaries of animals submitted to no treatment (intact), control treatments (E₂only and E₂+ RAdGFP) or IGF-I gene therapy (E₂+ RAd-IGF-I). Columns represent mean values whereas bars over columns represent SEM values. Five pituitaries per group were assessed. Asterisks indicate a highly significant difference from the intact group.

Figure 4

Effect of IGF-I gene therapy on lactotropic volume density (VD)

Effect of IGF-I gene therapy on lactotropic volume density (VD). Data correspond to the pituitaries of the same animals shown in Fig 3. Details are as in Fig. 3.

Effect of intrapituitary tumor IGF-I gene therapy on serum PRL levels

As expected, estrogen administration induced a marked hyperprolactinemia in the animals. Seven days after stereotaxic intrapituitary injection of RAd-IGF-I but not RAd-GFP, a significant fall in serum PRL occurred in the estrogen-treated rats (Fig. 5). Nevertheless, serum PRL of the RAd-IGF-I-treated rats remained higher than in the intact rats.

Figure 5

Effect of IGF-I gene therapy on serum PRL levels

Effect of IGF-I gene therapy on serum PRL levels. Serum PRL was measured in blood samples serially taken from Experimental day -23 to Experimental day 7. The number of rats used was 5 for all groups except for group E₂+ RAd-IGF-I where 7 animals were assessed Asterisks indicate significant differences from serum PRL on experimental day 0 (vector injection); *: P < 0.05; **: P < 0.01. Other details are as in Fig. 3

Discussion

Current therapies for pituitary tumors include surgery and radiotherapy, as well as pharmacological approaches for some types and, although important advances have been made in the treatment of pituitary tumors with these strategies, a fully satisfactory therapy is not yet available 14. In this context, gene therapy appears as a potentially useful alternative for the treatment of pituitary tumors.

Early studies showed that a herpes simplex virus type-1 (HSV1)-derived vector was highly effective in vivo for gene transfer in rat pituitary prolactinomas 15. An adenoviral vector, RadTK, harboring the HSV-1 thymidine kinase (TK) suicide gene under the control of the human cytomegalovirus (hCMV) promoter, was used to transfer the TK gene to GH₃and AtT₂₀rodent pituitary tumor cells. Incubation of RadTK-treated GH₃and AtT₂₀cells with the prodrug ganciclovir (which after phosphorylation by viral TK becomes toxic) caused ample destruction of the cultures 16. In the same study, estrogen/sulpiride-induced rat prolactinomas were stereotaxically injected with the same RadTK. Subsequent injection of the host animals with two daily intrapituitary doses of 25 mg ganciclovir/kg for 7 days succeeded in partially reducing tumor size and serum PRL levels. Another type of gene therapy strategy for the treatment of pituitary cancer is that based on the transfer of a gene(s) with the ability to rescue the normal phenotype of tumor cells. This approach has been implemented in mice heterozygous for the retinoblastoma (RB) tumor suppressor gene (Rb^+/-mice) which develop and succumb to characteristic pituitary intermediate lobe melanotroph tumors 17. Intracranial delivery of an adenoviral vector harboring the human RB cDNA to mice carrying actively growing melanotrophic tumors significantly reduced tumor growth and prolonged animal survival 18.

The present study is the first to implement effective pituitary tumor gene therapy using the gene for a bioactive peptide. Within the time frame used, the treatment seems to act mainly on PRL cell size and secretory activity rather than on PRL cell density (CD, data not shown). Our results are consistent with the above mentioned reports documenting that large estrogen-induced pituitary adenomas possess decreased pituitary levels of IGF-I mRNA and that the anti-estrogen tamoxifen increased the IGF-I mRNA content in the involuting adenomas 11. Our results are also consistent with the evidence that in rat lactotrophs, estrogen has an antiproliferative action in the presence of insulin or IGF-I 1213. Furthermore, our data showing that IGF-I gene therapy reduces PRL secretion in estrogen-induced prolactinomas are in line with an early study in rat pituitary cells reporting that IGF-I inhibited the estrogen induced rise in PRL and lactotroph pituitary transcription factor-1 (Pit-1) mRNA levels in females. This study also documented that the inhibitory effect of IGF-I on estrogen-induced PRL and lactotroph Pit-1 mRNA levels did not occur in male pituitary cells 19.

The mechanism by which pituitary overexpression of IGF-I reduces lactotropic cell size and inhibits PRL secretion is not clear. Although estrogen is known to increase pituitary expression of IGF-I mRNA, it also increases the expression of IGF binding protein 2 (IGF-BP2) mRNA 10. Since our approach involves pituitary overexpression of transgenic IGF-I, probably not paralleled by a concomitant increase in IGF-BP2, the possibility exists that high levels of free IGF-I exert an inhibitory action on the lactotrophs. It is well-established that IGF-I exerts a potent negative feedback on somatotropic cells 202122. Since lactotrophs and somatotrophs have a common origin and share a number of physiologic features, it seems conceivable that high pituitary concentrations of free IGF-I could have an inhibitory action on lactotropic cells. Clearly, further work is necessary to clarify this matter.

Methods

Adenoviral vectors

RAd-IGFI

A recombinant adenoviral (RAd) vector harboring the rat IGF-I gene (kindly donated by Dr. Peter Rotwein, Oregon Health Sciences University) was constructed in our laboratory by a variant of the two plasmid method employing the AdMax^®plasmid kit (Microbix, Ontario, Canada) 23. Briefly, the cDNA coding for rat IGF-I gene (obtained from the mRNA for the IGF Ib precursor form 24) was excised from plasmid pBluescript KS, subcloned in pCA14 and inserted in the multiple cloning site (MCS) of shuttle pDC515 which contains an expression cassette consisting of the mouse cytomegalovirus promoter (mCMV) and the simian virus 40 (SV40) polyadenylation signal, immediately upstream and downstream to the MCS, respectively. The second plasmid of the kit, the genomic plasmid pBHGfrt(del)E1,3 FLP, consists of the entire genome of adenovirus 5 (Ad5), containing deletions in the regions E1 and E3. In cotransfected HEK293 cells, FLP recombinase is readily expressed and efficiently catalyzes the site-directed recombination of the expression cassette of pDC515 into pBHGfrt(del)E1,3 FLP, thus generating the genome of the desired recombinant adenoviral vector, RAd-IGF-I (Fig. 6). The newly generated RAd was rescued from HEK293 cell lysates and plaque purified. It was further purified by ultracentrifugation in CsCl gradient. Final virus stocks were titrated by a serial dilution plaque assay.

Figure 6

Diagrammatic representation of the procedure used to construct RAd-IGF-I

Diagrammatic representation of the procedure used to construct RAd-IGF-I. An expression cassette containing the rat IGF-I cDNA (form B) flanked by the mCMV promoter (PmCMV) and the SV40 polyadenylation signal (SV40pA), upstream and downstream, respectively, was inserted in the shuttle vector pDC515. Subsequently, pDC515 and the genomic plasmid pBHGfrt(del)E1,3 FLP (which consists of the entire genome of adenovirus 5 (Ad 5), containing deletions in the regions E1 and E3) were cotransfected in permissive HEK 293 cells. Enzyme-directed recombination occurred in cotransfected cells, giving rise to RAd-IGFI. frt, recognition element for the yeast FLP recombinase; ITR, inverted terminal repeats; Δ1 and Δ3: deletions in the Ad 5 genome.

RAd-(GFP/TK)fus

An adenoviral vector termed RAd-(GFP/TK)fus, or RAd-GFP for short, was constructed in our laboratory following the general procedures outlined above and was used as a control vector in the gene therapy studies. The vector harbors a hybrid gene encoding the Aequorea victoria enhanced green fluorescent protein fused to herpes simplex virus type 1 thymidine kinase (GFP/TK)fus (a kind gift from Dr. Jacques Galipeau, McGill University, Montreal, Canada). This hybrid gene is driven by the mouse CMV promoter. The vector was expanded in 293 cells and purified and titrated as indicated above.

Animals

Young female Sprague-Dawley rats were housed in a temperature-controlled room (22 ± 2°C) on a 12:12 h light/dark cycle. Food and water were available ad libitum. All experiments with animals were done following the Animal Welfare Guidelines of NIH (INIBIOLP's Animal Welfare Assurance No A5647-01).

Experimental design for in vivo IGF-I gene therapy

At experimental day -23 all animals but those of the intact group, were subcutaneously implanted a silastic capsule filled with 17-β estradiol. Small blood samples (0.4 ml) were taken from the tail veins of all rats on experimental day -16, -9, 0, day +2 and day +7 for PRL assay. On experimental day 0, some of the rats received bilateral 1.5 μl intrapituitary injections containing 3 × 10⁹plaque forming units (pfu) of either RAd-GFP or RAd-IGF-I, respectively. For this purpose, rats were anesthetized with injection of ketamine hydrochloride (40 mg/kg, i.p.) and xylazine (8 mg/kg, i.m.), and placed in a stereotaxic frame. In order to access the pituitary region, the tip of a 26 gauge needle fitted to a 10 μl syringe was brought to the following coordinates relative to the bregma: 5.5 mm posterior, 9.6 mm ventral and 0.7 mm right and left 25. One week after intrapituitary injection rats were killed by decapitation. Pituitaries were immediately dissected, fixed and processed for routine histological studies.

Immunohistochemistry

Stated in brief, pituitary tissues from 5 animals of each group were fixed in Bouin's fluid and embedded in paraffin. Serial sections of 4 μm were obtained at different levels of the blocks following a ventral-to-dorsal sequence. The sections were immunostained, and then incubated for 1 h at room temperature with the anti-PRL primary antiserum (murine, Dako, CA, USA), diluted 1:100. Thoroughly washed sections were then treated for 30 min with a ready-to-use EnVision reaction system (Dako, CA, USA). The peroxide-sensitive chromogen was diaminobenzidine. In all instances, the specificity of the primary antiserum was monitored either by observing its ability to block the immunocytochemical reaction after its preabsorption with an excess of the related antigen or by its replacement with normal rabbit serum or phosphate-buffered saline 26.

Image analysis

Morphometry was performed as reported in detail previously 27. Measurements of pituitary cells were made by means of an image-analysis system (Imaging Technology, Optimas 5.2). The immunostained lactotrope cells and the reference area (RA) were analyzed in each field on an average of ten micrographs taken from two levels (e.g. a and b) in the groups studied. These measurements were recorded and processed automatically and the following parameters subsequently calculated: volume density (VD = Σ cell area/RA) and cell size (CS) (the mean of individual cell area, expressed in μm2). Reference area (RA) represents the adenohypophyseal (pars distalis) area scanned, in which pituitary PRL cells were scored. Then, with the sum (Σ) of the individual areas (A), referred to as RA, we obtained volume density (VD), which indicates cell mass according to a generally accepted concept.

Hormone assays

Serum levels of PRL were measured by a specific radioimmunoassay using the rat materials provided by Dr. A. F. Parlow, Pituitary Hormones and Antisera Center, UCLA Med. Center, U.S.A. Iodination grade hormones were radiolabeled by the Iodo-Gen^®method and purified on PD-10 Sephadex^®G-25 M columns (Pharmacia, Uppsala, Sweden) equilibrated with 0.01 M phosphosaline, pH 7.6. A 1/10 goat anti-rabbit IgG in 0.9% NaCl was used to separate bound from free hormone. Serum concentrations of PRL were expressed in terms of NHPP rPRL RP-3.

Statistical analysis

The one way analysis of variance (ANOVA) were used to evaluate group differences. Tukey's method was chosen as a post hoc test. In Figs. 3 and 4 pair comparisons were made between intact and each of the other experimental groups. Also, RAd-GFP vs. RAd-IGF1 pairs were compared in both figures. In Fig. 5 one-way ANOVA was applied to each set of data (intact, E2, etc) and pair comparisons were made between Exptl. Day 0 and each of the other time points.

Authors' contributions

GMC supervised the morphometric analysis of the pituitaries and made a major contribution to the preparation of the manuscript; CBH constructed the viral vectors used and performed the surgical procedures; GAC and GML executed the different aspects of the morphometric analysis of pituitaries; MIB carried out the histological procedures involved in this study; GRM performed the studies involving immunofluorescence analysis; RGG conceived of the study and participated in its design and coordination as well as in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors are indebted to Mrs. C. Ferese for the technical assistance. This study was supported in part by grant 11/M105 from the National University of La Plata and CIC-PBA to GMC and # PICT13588 from the National Agency for the Promotion of Science and Technology to RGG. RGG and GMC are CONICET and CIC-PBA career researchers, respectively.

Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus Daniels GH Martin JB Harrison's Principles of Internal Medicine New York: McGraw-Hill Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL 1995 1891 1918 Burek JD Pathology of aging rats Boca Raton: CRC Press 1978 Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland Lloyd RV Am J Pathol 1983 113 198 206 1916372 6638150 Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting tumors Sarkar DK Gottschall PE Meites J Science 1982 218 684 686 10.1126/science.7134966 7134966 Oral contraceptive use and the occurrence of pituitary prolactinoma Shy KK McTiernan AM Daling JR Weiss NS J Am Med Assoc 1983 249 2204 2207 10.1001/jama.249.16.2204 Prolactin stimulation using the metoclopramide test in females taking oral contraceptives Carol N Lauterbach H Klinger G Unger A Michels W Zentralbl Gynakol 1988 110 1515 1521 3149100 The effect of combined estrogen/progesterone treatment in women with hyperprolactinemic amenorrhea Fahy UM Foster PA Torodo HW Hartog M Hull MG Gynecol Endocrinol 1992 6 183 188 10.3109/09513599209015553 1442163 Pituitary cytokine and growth factor expression and action Ray D Melmed S Endocr Rev 1997 18 206 228 10.1210/er.18.2.206 9101137 Hormonal control of pituitary prolactin secreting tumors Sarkar DK Hentges ST De A Reddy RHR Frontiers in Bioscience 1998 3 934 943 Up-regulation of pituitary [125I]insulin-like growth factor-I (IGF-I) binding and IGF binding protein-2 and IGF-I gene expression by estrogen Michels KM Lee WH Seltzer A Saavedra JM Bondy CA Endocrinology 1993 132 23 29 10.1210/en.132.1.23 7678216 Independence of estrogen-induced pituitary proliferation on local IGF-I mRNA and EGF mRNA expression. Modifying effects of tamoxifen and terguride Hána V Haluzik M Schreiber V Physiol Res 1998 47 125 31 9706996 The estrogen-occupied estrogen receptor functions as a negative regulator to inhibit cell proliferation induced by insulin/IGF-1: a cell context-specific antimitogenic action of estradiol on rat lactotrophs in culture Kawashima K Yamakawa K Takahashi W Takizawa S Yin P Sugiyama N Kanba S Arita J Endocrinology 2002 143 2750 8 10.1210/en.143.7.2750 12072410 Estrogen actions on lactotroph proliferation are independent of a paracrine interaction with other pituitary cell types: a study using lactotroph-enriched cells Ishida M Takahashi W Itoh S Shimodaira S Maeda S Arita J Endocrinology 2007 148 3131 3139 10.1210/en.2006-1484 17412817 Management of pituitary tumors Shimon I Melmed S Annals Int Med 1998 129 472 483 <it>In vitro </it>and <it>in vivo </it>herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion Bolognani F Albariño C Romanowski V Carri NG Goya RG Eur J Endocrinol 2001 145 497 503 10.1530/eje.0.1450497 11581010 Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas Windeatt S Southgate TD Dewey RA Bolognani F Perone MJ Larregina AT Maleniak TC Morris ID Goya RG Klatzmann D Lowenstein PR Castro MG J Clin Endocr Metab 2000 85 1296 1305 10.1210/jc.85.3.1296 10720079 Heterozygous Rb_1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance Hu N Gutsmann A Herbert DC Bradley A Lee WH Lee EY Oncogene 1994 9 1021 1029 8134105 Adenovirus-mediated retinoblastoma gene therapy supresses spontaneous pituitary melanotroph tumors in Rb+/- mice Riley DJ Yu A Lee WH Nature Med 1996 2 1316 1321 10.1038/nm1296-1316 8946829 Sexually dimorphic interaction of insulin-like growth factor (IGF)-I and sex steroids in lactotrophs Chowen JA Gonzalez-Parra S Garcia-Segura LM Argente J J Neuroendocrinol 1998 10 493 502 10.1046/j.1365-2826.1998.00228.x 9700676 IGF-I action on rat anterior pituitary cells: effects of intracellular messengers on GH secretion and mRNA levels Morita S Yamashita S Melmed S Endocrinology 1987 121 2000 2006 3678137 Insulin-like growth factor-I regulation of growth hormone gene transcription in primary rat pituitary cells Yamashita S Melmed S J Clin Invest 1987 79 449 452 424098 3805277 Regulation of human GH gene expression by IGF-I in transfected cells Yamashita S Ong J Melmed S J Biol Chem 1987 262 13254 13257 3654610 Restorative effect of insulin-like growth factor-i gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction Hereñú CB Cristina C Rimoldi OJ Becú-Villalobos D Cambiaggi V Portiansky EL Goya RG Gene Therapy 2007 14 237 10.1038/sj.gt.3302870 16988717 Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations Daughaday WH Rotwein P Endocr Rev 1988 10 68 91 Paxinos G Watson C The rat brain in stereotaxic coordinates San Diego: Academic Press 1998 Ultrastructural and quantitative immunohistochemical changes induced by non steroid antiandrogens on pituitary gonadotroph population of prepuberal male rats Cónsole GM Jurado SB Rulli S Calandra RS Gómez Dumm CLA Cells Tissues & Organs 2001 169 64 72 10.1159/000047862 11340263 Influence of photoinhibition on the morphology and function of pituitary lactotropes in male golden hamster Cónsole GM Jurado SB Petruccelli M Carino M Calandra RS Gómez Dumm CLA Neuroendocrinology 2002 75 316 325 10.1159/000057341 12006785